This observation is important, for elevated sVAP-1 has also been described in patients with non-alcoholic fatty liver disease, predominantly those with a more advanced stage of fibrosis,12 although prognostic utility in a dedicated clinical outcomes' analysis was not evident in this cohort. Here, SNAP47 is linked to metabolic dysfunction-associated steatotic liver disease.